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a double balloon system introduced to optimize dose 
distribution. 
Toxicity and long-term oncological results: In the neo-
adjuvant setting, grade 3 radiation proctitis is observed in 
less than 0.5% of treated cases 7-10 days after treatment 
completion. In the boost setting, proctitis is observed 3-4 
weeks after the HDREBT treatment and included rectal 
bleeding in 25% of the patients, out of which 10% with 
anticoagulation required transfusion and plasma-argon 
therapy. In 3 patients with circumferential tumors, rectal 
stenosis was documented. Rectal ulcerations can be observed 
5-9 months after treatment but do improve over time. 
Overall for low T2 and T3 tumors, HDREBT resulted with a 
pCR rate of 27%, with the local recurrence of 4.8 % at 5 years 
with a median follow up time of 62 months. For the medically 
unfitted patients, with HDREBT used as a boost, the local 
control is 65% at a median 28 months follow up time. 
Conclusion: In the present era of rectal preservation, the 
HDEBT represents a highly targeted radiation modality that is 
effective as neo-adjuvant and boost treatment modalities for 
patients with rectal cancer. 
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Surgery main Treatment of rectal cancer often combined 
with neoadjuvant (chemo) radiotherapy (CRT).  
Despite improvement in local control for T2-3(4) tumors, CRT 
failed to improve conservative treatment in rectal cancer. 
Anterior resection is often associated with suboptimal bowel 
function. Organ preservation (whole rectum + anus) is gaining 
interest mainly for early (T1) T2 T3 tumors. 
CXB: a unique technique of trans-rectal endoscopic 
Brachytherapy Evidence Based.  
Mainly pioneered by Papillon in the 1970s the technique is 
presenting a renaissance since 2009 (1) with the manufacture 
of a new machine delivering high dose rate of 50 Kvp X-rays( 
Papillon 50TM). Under direct endoscopic vision control it is 
possible to deliver 30 Gy in 2 minutes in a well-targeted small 
volume (5 cm3). It is a fully ambulatory treatment feasible at 
any age with very low toxicity. The dose distribution is better 
than with Iridium endoluminal HDR brachytherapy and 
radioprotection is easier. The Lyon R 96-02 randomized trial 
(2-3) has demonstrated with a 10 year follow-up that CXB 
boost combined with External beam RT in T2 -3 low rectum 
was able to increase by 30% the rate of clinical complete 
response, of sphincter saving surgery and of organ 
preservation in case of cCR. The rate of perirectal nodal 
relapse is below 5%. 
Present results in France and UK show good results for 
organ preservation in selected T1 T2 and early T3  
In T1 N0 (or malignant polyps) treated with local Excision 
first (63 pts between 1986-2012 in Lyon and Nice), adjuvant 
CXB (50 Gy/ 3 fr/ 3w) achieved local control in 95% of cases 
with good bowel function. In T2 T3 less than ½ circumference 
and < 5cm diameter a combination of CXB and EBRT (or CRT), 
mainly in elderly frail patients, achieved cCR in close to 90% 
of cases (Lyon-Nice: 120 pts) with less than 20% local relapse 
very exceptional in perirectal lymph nodes (4-5). In 
Clatterbridge-Liverppool same results were achieved in the 
recent past years in more than 150 pts. Such combined CXB+ 
CRT appears as a very good option for frail patients or for 
younger patients adamantly refusing an invasive surgery.  
Many challenges remain open 
In operable patients the upcoming OPERA randomized trial 
will like the Lyon R96-02 try to show that CXB in addition to 
CRT (CAP 45) may achieve in T2 T3a-b at least 40% of organ 
preservation with good bowel function. The new machine 
Papillon+TM will bring some technical improvements. But the 
most important issue is that radiation oncologists willing to 
use CXB must get a good clinical practice of rigid rectoscopy 
on an ambulatory basis. 
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In the treatment of rectal cancer, total mesorectal excision 
surgery is now the standard of care. In most patients, surgery 
will be preceded by external beam radiotherapy (EBRT), 
either in a short course (25 Gy/5 fractions) or in a 
conventional schedule (45-50 Gy/25 fractions) with 
chemotherapy. Brachytherapy (BT) is an appealing 
alternative to EBRT.  In comparison to the EBRT, it offers the 
advantage of delivering a high dose of radiation with a rapid 
dose fall-off around the site of interest (tumor target). This 
results in the sparing of normal tissues such as small bowel 
but also the bladder, the prostate, anal sphincter and skin.  
In order to understand why brachytherapy may work as 
replacement for external beam radiotherapy, an exact target 
volume definition for rectal cancer is required, based on 
precise data on the local recurrence patterns. The decision 
which nodal regions should be included in the clinical target 
volume is often topic of discussion. In general, it can be 
stated that the highest risk of lymph node involvement is in 
the mesorectal fat. In addition, the presacral space and the 
internal iliac region are at risk. Depending on the exact 
localization and tumor stage, the obturator nodes, the 
external iliac nodes and the inguinal nodes may sometimes be 
affected. For years, this has lead to a more or less standard 
clinical target volume, including the primary tumor, the 
mesorectal fat and the presacral and internal iliac lymph 
node regions. However, given the limited number of 
recurrences after TME surgery, the standard clinical target 
volume can be seriously questioned. 
Another interesting application of endoluminal brachytherapy 
is the ability to increase the dose on the primary tumour. In 
elderly patients, standard surgery may be hampered by the 
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fact that the risk of morbidity and mortality can be too high. 
For these patients unfit for surgery, definitive radiotherapy is 
an option that should seriously be considered. This, however, 
requires a higher dose on the primary tumour, to increase the 
likelihood of complete response. In this respect, 
brachytherapy (BT) is an appealing treatment modality.  In 
comparison to external beam radiotherapy, it offers the 
advantage of delivering a high dose of radiation with a rapid 
dose fall-off around the site of interest (tumour target).  
From published studies it is clear that for relatively small 
tumours, local treatment with either contact X-rays or 
intraluminal brachytherapy is a reasonable option. For 
patients with larger tumours, the risk of nodal involvement 
makes the combination of local radiotherapy with external 
beam radiotherapy necessary.  
So far, this combination has mainly been given with contact 
X-rays and only sporadically with intraluminal brachytherapy. 
In this presentation, a summary of published studies will be 
given, with an update on the HERBERT trial, a brachytherapy 
trial for medically unfit patients with T2-T4 rectal tumours. 
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Prostate cancer is a major health issue in aging men. No 
treatment is required in less aggressive prostate cancer but 
there is consensus that radical treatment is needed in 
aggressive prostate cancer. Radical treatment has to start 
while the tumor is still confined to the gland and has not 
spread beyond. Potential side effects of radical treatment, 
such as impotence and incontinence, have a substantial 
impact on quality of life. This is of special importance 
because more than 25% of patients eligible for radical 
treatment are in the age range of 40 to 65 years. 
Conventional anatomical T2-weighted MR imaging is the 
mainstay in prostate cancer imaging. On T2-weighted MR 
images, normal prostate tissue displays an intermediate to 
high signal intensity while the central gland has lower signal 
intensity than the peripheral zone. Currently several new MR 
imaging techniques are being explored. These include: 1H-MR 
spectroscopic imaging (MRSI), dynamic contrast-enhanced MR 
imaging (DCE-MRI), and diffusion weighted imaging (DWI).  
MRSI is a unique method that can provide information based 
on tumor metabolism. The chemical environment of protons 
within a certain molecule defines their so-called chemical 
shift: a unique resonance frequency when positioned in a 
magnetic field, which can be observed in an MR spectrum. 
Specific spectral profiles reflect the identity of (bio-) 
chemicals present at that location and the intensity of the 
spectral signals is related to the tissue levels of these 
compounds. Analytical and clinical studies have shown 
significant differences of the metabolic state of the different 
tissue types by MRSI. 
Dynamic contrast-enhanced MR imaging – with a low 
molecular weight contrast media (<1 kDa) enables non-
invasive imaging of tumor angiogenesis. DCE-MRI is the most 
common imaging method for evaluating human tumor 
vascular function in situ. Insights into these physiologic 
processes are obtained qualitatively by characterizing kinetic 
enhancement curves or quantitatively by applying complex 
compartmental modeling techniques. Data reflecting the 
tissue perfusion (blood flow, blood volume, and mean transit 
time), the microvessel permeability, and the extracellular 
leakage space can be obtained. 
Diffusion weighted MR imaging – can quantify the water 
motion in an indirect manner. The DWI pulse sequence labels 
hydrogen nuclei in space, of which most will be part of water 
molecules at any moment, and determines the length of the 
path that water molecules travel over a short period of time. 
DWI is able to estimate the mean distance traveled by all 
hydrogen nuclei in every voxel of imaged tissue. The greater 
this mean distance the more self-diffusion of water 
molecules has taken place in a certain time interva . From 
this estimate an apparent diffusion coefficient (ADC) as a 
reflection of the self-diffusion of water in tissue in a certain 
direction can be calculated. 
Multiple studies have explored optimal parameter settings for 
the diagnostic MR-protocol, which allows accurate tumor 
localization and tumor volume assessment. Although reported 
accuracies of the different separate and combined 
multiparametric MR imaging techniques vary for diverse 
clinical prostate cancer indications, multiparametric prostate 
MR imaging has shown promising results and may be of 
additional value in prostate cancer localization and local 
staging. To increase MR imaging accuracy for the different 
clinical prostate cancer indications, one or more functional 
MR imaging techniques should be combined with T2-weighted 
MR imaging in a multiparametric MR imaging exam of the 
prostate. 
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High dose rate (HDR) brachytherapy can deliver a high, 
localised radiation dose to the prostate which results in 
excellent biochemical control of prostate cancer. Multi-
parametric magnetic resonance imaging (mpMRI) can be used 
to define regions within the prostate that are at highest risk 
of containing clinically significant tumour. Incorporation of 
these multi-parametric datasets into the HDR brachytherapy 
planning process facilitates ‘dose painting’ where regions of 
greatest risk are given a higher radiotherapy dose using an 
inhomogeneous plan (figure). 
 
 
Figure: HDR brachytherapy with focussed dose escalation. A 
dominant intra-prostatic lesion (DIL) in the right postero-
lateral peripheral zone has been defined using multi-
parametric MRI. High dose rate brachytherapy catheters 
have been inserted under general anaesthetic. The planning 
computer optimisation software has been programmed to 
maximise the radiation dose to the DIL and limit the dose to 
the rest of the prostate to a defined ceiling.  
